AMS AMERICAN SHARED HOSPITAL SERVICES
Services-Medical Laboratories · NYSE · SEC CIK 744825 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.9%
TTM net income YoY-5.6%
TTM EPS YoY0.0%
Revenue 3-yr CAGR14.3%
Net income 3-yr CAGR—
Margins
Gross margin16.7%
Operating margin-13.0%
Net margin-7.7%
FCF margin22.4%
EBITDA margin4.2%
Returns
ROE-10.1%
ROA-4.2%
ROIC (approx.)-9.0%
Asset turnover0.55x
Leverage & solvency
Liabilities / assets52.7%
Debt / equity0.77x
Current ratio0.81x
Interest coverage-2.85x
Cash quality & payout
Operating cash flow / net income-2.15x
Accruals ratio-13.3%
Payout ratio—
Capex / revenue-5.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.62M | $8.43M | $7.08M | $7.73M | $7.17M | $7.07M | $6.11M | $9.07M |
| Cost of revenue | $6.11M | $7.00M | $5.80M | $6.82M | $5.58M | $5.44M | $5.17M | $5.87M |
| Gross profit | $1.52M | $1.43M | $1.29M | $906,000 | $1.59M | $1.63M | $942,000 | $3.20M |
| SG&A expense | $1.80M | $2.04M | $1.91M | $1.99M | $1.54M | $1.75M | $1.81M | $1.71M |
| Operating income | -$764,000 | -$910,000 | -$924,000 | -$1.40M | -$344,000 | -$544,000 | -$1.30M | -$1.83M |
| Interest expense | $480,000 | $301,000 | $302,000 | $321,000 | $392,000 | $428,000 | $433,000 | $429,000 |
| Pretax income | -$743,000 | -$863,000 | -$870,000 | -$1.21M | -$281,000 | -$499,000 | -$1.24M | -$1.94M |
| Income tax | $163,000 | $135,000 | $92,000 | -$197,000 | $48,000 | -$21,000 | -$323,000 | -$51,000 |
| Net income | -$620,000 | -$514,000 | -$612,000 | -$631,000 | -$17,000 | -$280,000 | -$625,000 | -$1.33M |
| EBITDA | $578,000 | $436,000 | $370,000 | -$98,000 | $1.11M | $964,000 | $150,000 | -$157,000 |
| EPS (basic) | -0.09 | -0.07 | -0.09 | — | 0.00 | -0.04 | -0.10 | — |
| EPS (diluted) | -0.09 | -0.07 | -0.09 | — | 0.00 | -0.04 | -0.10 | — |
| Weighted avg. shares (diluted) | 6.77M | 6.87M | 6.72M | — | 6.63M | 6.58M | 6.57M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.23M | $6.51M | $4.97M | $3.46M | $5.09M | $11.08M | $11.24M | $11.03M |
| Receivables | $7.64M | $8.32M | $10.57M | $10.52M | $11.81M | $9.58M | $8.74M | $11.61M |
| Current assets | $19.06M | $17.37M | $18.27M | $17.72M | $20.59M | $24.43M | $23.74M | $26.26M |
| PP&E, net | — | — | — | — | — | — | — | $72.85M |
| Goodwill | $1.26M | $1.26M | $1.26M | $1.26M | $1.26M | $1.26M | $1.26M | $1.26M |
| Intangibles | $78,000 | $78,000 | $78,000 | $78,000 | $78,000 | $78,000 | $78,000 | $78,000 |
| Total assets | $52.87M | $52.49M | $54.73M | $55.48M | $59.63M | $63.49M | $63.31M | $60.20M |
| Current liabilities | $23.63M | $22.42M | $23.72M | $23.44M | $25.80M | $20.86M | $12.71M | $10.40M |
| Short-term debt | — | $16.22M | $16.84M | $17.29M | $18.18M | $9.87M | $3.13M | $2.84M |
| Long-term debt | $17.49M | $16.22M | $16.84M | $0 | $0 | $9.22M | $16.80M | $17.34M |
| Total debt | $17.49M | $32.43M | $33.69M | $17.29M | $18.18M | $19.09M | $19.93M | $20.18M |
| Total liabilities | $27.84M | $26.68M | $28.02M | $27.79M | $31.03M | $34.65M | $34.10M | $30.17M |
| Shareholders' equity | $22.61M | $23.11M | $23.52M | $24.03M | $24.57M | $24.48M | $24.65M | $25.18M |
| Net debt | $10.26M | $25.92M | $28.71M | $13.83M | $13.09M | $8.01M | $8.69M | $9.16M |
| Shares outstanding | 6.65M | 6.62M | 6.60M | 6.58M | 6.51M | 6.48M | 6.45M | 6.42M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.42M | $2.24M | $2.15M | -$704,000 | $1.67M | -$372,000 | $2.50M | $274,000 |
| Capital expenditure | $76,000 | $58,000 | $41,000 | -$1.98M | $3.70M | $1.90M | $4.01M | $4.66M |
| Free cash flow | $1.35M | $2.18M | $2.11M | $1.28M | -$2.03M | -$2.27M | -$1.51M | -$4.39M |
| Investing cash flow | -$76,000 | -$58,000 | -$41,000 | $1.98M | -$3.70M | -$1.90M | -$4.01M | -$4.37M |
| Financing cash flow | $1.38M | -$640,000 | -$597,000 | -$2.91M | -$3.96M | $2.11M | $1.73M | $1.29M |
| Depreciation & amortization | $1.34M | $1.35M | $1.29M | $1.30M | $1.45M | $1.51M | $1.45M | $1.67M |
| Stock-based compensation | $38,000 | $102,000 | $101,000 | $100,000 | $101,000 | $114,000 | $89,000 | $88,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.